Spinal cannabinoid receptor 2 activation alleviates neuropathic pain by regulating microglia and suppressing P2X7 receptor

by Selleckchem | Nov 19 2023

Neuropathic pain (NP) is the chronic pain in patients resulting from injuries or diseases in the somatosensory nervous system. However, effective treatment remains limited to opioids. Currently, there is an urgent need to develop new specific pharmaceuticals with low abuse potentiality. Cannabinoid receptor 2 (CB2R) is one of the significant receptors in the endocannabinoid system. It is widely expressed in the central nervous system, especially enriched in glial cells, and plays an important role in the occurrence and development of inflammation in the nervous system. CB2R activation has a neuroprotective effect on nerve injury. In this study, we report increased and more reactive microglia (with larger cell body, shorter processes, and fewer endpoints) observed in the spinal dorsal horn of spared nerve injury (SNI) rats. Continuous intrathecal administration of CB2R agonist PM226 attenuated mechanical and cold hyperalgesia in rats and prevented the transition of microglia to the proinflammatory stage. Thus, microglia transitioned into the neuroprotective stage. Meanwhile, the proinflammatory factors TNF-α and iNOS decreased, and the levels of anti-inflammatory factors Arg-1 and IL-10 increased. The content of P2X7 receptors in the spinal dorsal horn of rats increases with time after SNI. After continuous intrathecal administration of PM226, the content of P2X7 protein decreases significantly. The administration of P2X7 inhibitor A-438079 alleviated the mechanical hyperalgesia of rats, reduced the number of microglia, and decreased the content of P2X7. These results indicate that P2X7 is involved in the neuroprotective effect caused by CB2R activation. In conclusion, this study provides new insights into the neuroprotective mechanism of CB2R activation.

Comments:

The study you've described provides valuable insights into the potential neuroprotective mechanism of CB2R activation in the context of neuropathic pain. Neuropathic pain is a challenging condition to treat, and understanding the underlying mechanisms is crucial for developing effective therapies with lower abuse potential. Here's a summary of the key findings and implications of the study:

1. **Background:**
- Neuropathic pain (NP) is a chronic pain condition resulting from somatosensory nervous system injuries or diseases.
- Current treatments are limited to opioids, highlighting the need for new, safer pharmaceutical options.

2. **CB2R and Neuroprotection:**
- CB2R, a significant receptor in the endocannabinoid system, is widely expressed in the central nervous system, especially in glial cells.
- CB2R activation has a neuroprotective effect on nerve injuries.

3. **Microglial Activation and Transition:**
   - The study observed increased and more reactive microglia in the spinal dorsal horn of rats with spared nerve injury (SNI).
   - Continuous administration of CB2R agonist PM226 led to a transition of microglia from a proinflammatory stage to a neuroprotective stage.
   - This transition was characterized by decreased proinflammatory factors (TNF-α and iNOS) and increased anti-inflammatory factors (Arg-1 and IL-10).

4. **Involvement of P2X7 Receptors:**
   - The study found that the content of P2X7 receptors in the spinal dorsal horn increased over time after SNI.
   - Continuous administration of CB2R agonist PM226 significantly decreased P2X7 protein content.
   - Administration of the P2X7 inhibitor A-438079 alleviated mechanical hyperalgesia, reduced microglia numbers, and decreased P2X7 content.

5. **Conclusion:**
   - CB2R activation, particularly by the specific agonist PM226, demonstrated a neuroprotective effect in neuropathic pain models.
   - This neuroprotection was linked to the transition of microglia from a proinflammatory to a neuroprotective stage, as well as the modulation of P2X7 receptors.
   - Understanding these mechanisms could pave the way for the development of novel, targeted therapies for neuropathic pain with lower abuse potential.

In summary, the study provides promising evidence regarding the potential of CB2R activation and its interplay with microglia and P2X7 receptors in managing neuropathic pain. Further research in this area could lead to the development of safer and more effective pharmaceuticals for patients suffering from neuropathic pain.